Company highlights growing contracted project activity, expanding pharmaceutical engagements, initial commercial activation of CRO channel and continued scientific progressTORONTO, Aug. 20, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (TSX: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), an artificial intelligence company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today provided an update on recent commercial, strategic and oper ...